REVERSE-LC clinical trial update: I had a good 3-4 weeks followed by increasing symptoms and fatigue. I'm certain I'm on 4 mg of baricitinib bc I've needed extra labs. I've now lost 10% kidney function 😬 so dropping to 2 mg.
I know we'll crack this thing, but long covid is really hard
I know we'll crack this thing, but long covid is really hard
November 21, 2025 at 5:19 PM
REVERSE-LC clinical trial update: I had a good 3-4 weeks followed by increasing symptoms and fatigue. I'm certain I'm on 4 mg of baricitinib bc I've needed extra labs. I've now lost 10% kidney function 😬 so dropping to 2 mg.
I know we'll crack this thing, but long covid is really hard
I know we'll crack this thing, but long covid is really hard
My baricitinib arrives today !!!! (before and after)
August 20, 2026 at 10:38 PM
My baricitinib arrives today !!!! (before and after)
Olumiant (baricitinib) is working - it is so funny growing pale baby fuzz when I was expecting dark stubble (of course! it's growing from scratch)
September 30, 2026 at 9:45 PM
Olumiant (baricitinib) is working - it is so funny growing pale baby fuzz when I was expecting dark stubble (of course! it's growing from scratch)
Baricitinib trial website just launched! This is a large, phase 3 trial funded by the NIH (but outside of RECOVER). Baricitinib is approved for rheumatoid arthritis, is an immunomodulator, and one of the few drugs effective for acute Covid infection (it's used in hospitalized patients).
'Reverse LC - Federally funded by the NIH'
'People living with Long COVID are looking for answers'
'REVERSE-LC is a study to see if a drug called Baricitinib can help'
www.reversinglongcovid.org
'People living with Long COVID are looking for answers'
'REVERSE-LC is a study to see if a drug called Baricitinib can help'
www.reversinglongcovid.org
REVERSE-LC
People living with Long COVID are looking for answers. REVERSE-LC is a study to see if a drug called Baricitinib can help.
www.reversinglongcovid.org
November 17, 2024 at 5:46 PM
Baricitinib trial website just launched! This is a large, phase 3 trial funded by the NIH (but outside of RECOVER). Baricitinib is approved for rheumatoid arthritis, is an immunomodulator, and one of the few drugs effective for acute Covid infection (it's used in hospitalized patients).
🆕💥“Baricitinib: The Immunomodulator of Choice for Severe COVID-19—The Verdict Is in”
Carlos Gomez and I just published this new article:
#IDSky #MedSky #PCCSky #ICUSky #emimcc #Ansky #EMSky #AMSSky #TxID #meded #Pharmsky #RXSky@unmc.bsky.social@unmccom.bsky.social
👇
bit.ly/4gd1gdS
Carlos Gomez and I just published this new article:
#IDSky #MedSky #PCCSky #ICUSky #emimcc #Ansky #EMSky #AMSSky #TxID #meded #Pharmsky #RXSky@unmc.bsky.social@unmccom.bsky.social
👇
bit.ly/4gd1gdS
Baricitinib: The Immunomodulator of Choice for Severe... : Critical Care Medicine
An abstract is unavailable.
bit.ly
December 6, 2024 at 4:18 AM
👩🔬The NIH REVERSE-LC clinical trial for #longcovid is recruiting! Led by @weselymd.bsky.social
🧪550 patients in the US (4 sites)
🧪Testing Baricitinib to see if it improves neurocognitive function
Baricitinib regulates inflammation/immune response through the Janus kinase protein
🧪550 patients in the US (4 sites)
🧪Testing Baricitinib to see if it improves neurocognitive function
Baricitinib regulates inflammation/immune response through the Janus kinase protein
REVERSE-LC
People living with Long COVID are looking for answers. REVERSE-LC is a study to see if a drug called Baricitinib can help.
buff.ly
January 28, 2025 at 6:05 PM
👩🔬The NIH REVERSE-LC clinical trial for #longcovid is recruiting! Led by @weselymd.bsky.social
🧪550 patients in the US (4 sites)
🧪Testing Baricitinib to see if it improves neurocognitive function
Baricitinib regulates inflammation/immune response through the Janus kinase protein
🧪550 patients in the US (4 sites)
🧪Testing Baricitinib to see if it improves neurocognitive function
Baricitinib regulates inflammation/immune response through the Janus kinase protein
People w/ #LongCovid may participate in a new clinical trial testing whether the drug baricitinib improves neurocognitive function & other functions diminished by Long Covid. Learn more about the trial led by Dr. Wesley Ely of
the Vanderbilt University Medical Center here:
ow.ly/paS250UOeWv
the Vanderbilt University Medical Center here:
ow.ly/paS250UOeWv
New Clinical Trial Will Test How Baricitinib Improves Neurocognitive Function in Patients with Long Covid - Solve ME/CFS Initiative
Patients with Long Covid may participate in an important new clinical trial—the REVERSE-LC trial (Evaluating Baricitinib on Persistent Neurologic and Cardiopulmonary Symptoms of Long COVID)—which will...
solvecfs.org
January 27, 2025 at 10:47 PM
People w/ #LongCovid may participate in a new clinical trial testing whether the drug baricitinib improves neurocognitive function & other functions diminished by Long Covid. Learn more about the trial led by Dr. Wesley Ely of
the Vanderbilt University Medical Center here:
ow.ly/paS250UOeWv
the Vanderbilt University Medical Center here:
ow.ly/paS250UOeWv
The Sick Times: “Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation”
‘abrocitinib (Cibinqo), baricitinib (Olumiant) & upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathways’
thesicktimes.org/2025/08/05/t...
‘abrocitinib (Cibinqo), baricitinib (Olumiant) & upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathways’
thesicktimes.org/2025/08/05/t...
Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation - The Sick Times
Three separate trials are testing the immunomodulator drugs abrocitinib (Cibinqo), baricitinib (Olumiant), and upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathway...
thesicktimes.org
August 5, 2025 at 6:11 PM
The Sick Times: “Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation”
‘abrocitinib (Cibinqo), baricitinib (Olumiant) & upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathways’
thesicktimes.org/2025/08/05/t...
‘abrocitinib (Cibinqo), baricitinib (Olumiant) & upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathways’
thesicktimes.org/2025/08/05/t...
Not to be a downer, but I felt nearly fully recovered on baricitinib. Now, about a month off the trial, symptoms are creeping back, and ngl it's devastating.
Hello unrelenting chest and joint pain, my old friends
Hello unrelenting chest and joint pain, my old friends
I've taken my last dose on the REVERSE Long Covid trial! I feel *so* much better than I did at baseline 6 mos ago. (Based on labs, was def on the baricitinib.) Really hope this gives others a boost and new treatment option!
Grateful for good science!!
Grateful for good science!!
Just took my first dose! Come on study drug!!
A strange feeling to be on the participant side of a study, but after 3.5 years of long covid, I could really, really use a win 🙏
A strange feeling to be on the participant side of a study, but after 3.5 years of long covid, I could really, really use a win 🙏
April 10, 2026 at 3:38 AM
Not to be a downer, but I felt nearly fully recovered on baricitinib. Now, about a month off the trial, symptoms are creeping back, and ngl it's devastating.
Hello unrelenting chest and joint pain, my old friends
Hello unrelenting chest and joint pain, my old friends
'New Clinical Trial Will Test How Baricitinib Improves Neurocognitive Function in Patients with Long Covid'
'The team is now recruiting 550 people from the continental US to participate'
solvecfs.org/new-clinical...
'The team is now recruiting 550 people from the continental US to participate'
solvecfs.org/new-clinical...
New Clinical Trial Will Test How Baricitinib Improves Neurocognitive Function in Patients with Long Covid - Solve ME/CFS Initiative
Patients with Long Covid may participate in an important new clinical trial—the REVERSE-LC trial (Evaluating Baricitinib on Persistent Neurologic and Cardiopulmonary Symptoms of Long COVID)—which will...
solvecfs.org
January 28, 2025 at 2:32 PM
'New Clinical Trial Will Test How Baricitinib Improves Neurocognitive Function in Patients with Long Covid'
'The team is now recruiting 550 people from the continental US to participate'
solvecfs.org/new-clinical...
'The team is now recruiting 550 people from the continental US to participate'
solvecfs.org/new-clinical...
I discovered that baricitinib costs $2,850 to $5,700 NZD for 30 days supply OMG that is so many wigs
July 12, 2026 at 10:31 PM
I discovered that baricitinib costs $2,850 to $5,700 NZD for 30 days supply OMG that is so many wigs
'Reverse LC - Federally funded by the NIH'
'People living with Long COVID are looking for answers'
'REVERSE-LC is a study to see if a drug called Baricitinib can help'
www.reversinglongcovid.org
'People living with Long COVID are looking for answers'
'REVERSE-LC is a study to see if a drug called Baricitinib can help'
www.reversinglongcovid.org
REVERSE-LC
People living with Long COVID are looking for answers. REVERSE-LC is a study to see if a drug called Baricitinib can help.
www.reversinglongcovid.org
November 17, 2024 at 5:43 PM
'Reverse LC - Federally funded by the NIH'
'People living with Long COVID are looking for answers'
'REVERSE-LC is a study to see if a drug called Baricitinib can help'
www.reversinglongcovid.org
'People living with Long COVID are looking for answers'
'REVERSE-LC is a study to see if a drug called Baricitinib can help'
www.reversinglongcovid.org
A meta-analysis of the 28 randomized trials assessing treatments for severe Covid nature.com/articles/s41... Data for IL-6 blockade (tocilizumab), baricitinib, remdesivir, and other drug interventions summarized
October 11, 2023 at 4:27 PM
A meta-analysis of the 28 randomized trials assessing treatments for severe Covid nature.com/articles/s41... Data for IL-6 blockade (tocilizumab), baricitinib, remdesivir, and other drug interventions summarized
Great @thesicktimes.org article on 3 upcoming #LongCovid trials on JAK inhibitors. PLRC did patient engagement and helped shape 1 of the 3 here, REVERSE-LC (baricitinib) led by @weselymd.bsky.social — who also used our scorecards for patient engagement! thesicktimes.org/2025/08/05/t...
Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation - The Sick Times
Three separate trials are testing the immunomodulator drugs abrocitinib (Cibinqo), baricitinib (Olumiant), and upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathway...
thesicktimes.org
September 17, 2025 at 8:25 PM
Great @thesicktimes.org article on 3 upcoming #LongCovid trials on JAK inhibitors. PLRC did patient engagement and helped shape 1 of the 3 here, REVERSE-LC (baricitinib) led by @weselymd.bsky.social — who also used our scorecards for patient engagement! thesicktimes.org/2025/08/05/t...
Based on the draft agenda shared yesterday, it seems that RECOVER-TLC has selected the following 4 agents to trial next for Long COVID treatment.
Low-Dose Naltrexone
Baricitinib
GLP-1 Receptor Agonists
Stellate Ganglion Block
What are your thoughts?
view.officeapps.live.com/op/view.aspx...
Low-Dose Naltrexone
Baricitinib
GLP-1 Receptor Agonists
Stellate Ganglion Block
What are your thoughts?
view.officeapps.live.com/op/view.aspx...
view.officeapps.live.com
August 5, 2025 at 5:01 PM
Based on the draft agenda shared yesterday, it seems that RECOVER-TLC has selected the following 4 agents to trial next for Long COVID treatment.
Low-Dose Naltrexone
Baricitinib
GLP-1 Receptor Agonists
Stellate Ganglion Block
What are your thoughts?
view.officeapps.live.com/op/view.aspx...
Low-Dose Naltrexone
Baricitinib
GLP-1 Receptor Agonists
Stellate Ganglion Block
What are your thoughts?
view.officeapps.live.com/op/view.aspx...
Have you taken a JAK STAT inhibitor for Long COVID or ME? I'm working on a story about these drugs (baricitinib, abrocitinib, upadacitinib, and others) which are currently being investigated in clinical trials for the disease.
Reach me at: miles@thesicktimes.org or dm for signal!
Reach me at: miles@thesicktimes.org or dm for signal!
April 25, 2025 at 12:11 AM
Have you taken a JAK STAT inhibitor for Long COVID or ME? I'm working on a story about these drugs (baricitinib, abrocitinib, upadacitinib, and others) which are currently being investigated in clinical trials for the disease.
Reach me at: miles@thesicktimes.org or dm for signal!
Reach me at: miles@thesicktimes.org or dm for signal!
Our team at UT Health San Antonio is currently recruiting for the REVERSE-LC trial for brain fog and fatigue in #LongCovid with baricitinib (Jak pathway inhibitor).
September 19, 2026 at 7:45 PM
Our team at UT Health San Antonio is currently recruiting for the REVERSE-LC trial for brain fog and fatigue in #LongCovid with baricitinib (Jak pathway inhibitor).
🔥Article d'un large consortium européen qui a évalué thérapies COVID-19
Essai clinique évaluant baricitinib chez patients COVID critique, mais du fait de l'évolution pandémie, objectif d'inclusion n'a pas été atteint
Néanmoins des résultats intéressants !
www.sciencedirect.com/science/arti...
Essai clinique évaluant baricitinib chez patients COVID critique, mais du fait de l'évolution pandémie, objectif d'inclusion n'a pas été atteint
Néanmoins des résultats intéressants !
www.sciencedirect.com/science/arti...
Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial
The Bari-SolidAct randomized controlled trial compared baricitinib with placebo in patients with severe COVID-19. A post hoc analysis revealed a highe…
www.sciencedirect.com
December 27, 2024 at 6:13 PM
🔥Article d'un large consortium européen qui a évalué thérapies COVID-19
Essai clinique évaluant baricitinib chez patients COVID critique, mais du fait de l'évolution pandémie, objectif d'inclusion n'a pas été atteint
Néanmoins des résultats intéressants !
www.sciencedirect.com/science/arti...
Essai clinique évaluant baricitinib chez patients COVID critique, mais du fait de l'évolution pandémie, objectif d'inclusion n'a pas été atteint
Néanmoins des résultats intéressants !
www.sciencedirect.com/science/arti...
I've taken my last dose on the REVERSE Long Covid trial! I feel *so* much better than I did at baseline 6 mos ago. (Based on labs, was def on the baricitinib.) Really hope this gives others a boost and new treatment option!
Grateful for good science!!
Grateful for good science!!
Just took my first dose! Come on study drug!!
A strange feeling to be on the participant side of a study, but after 3.5 years of long covid, I could really, really use a win 🙏
A strange feeling to be on the participant side of a study, but after 3.5 years of long covid, I could really, really use a win 🙏
March 12, 2026 at 10:27 AM
I've taken my last dose on the REVERSE Long Covid trial! I feel *so* much better than I did at baseline 6 mos ago. (Based on labs, was def on the baricitinib.) Really hope this gives others a boost and new treatment option!
Grateful for good science!!
Grateful for good science!!
A website has launched for the baricitinib trial for Long Covid, if you’d like to participate www.reversinglongcovid.org
REVERSE-LC
People living with Long COVID are looking for answers. REVERSE-LC is a study to see if a drug called Baricitinib can help.
www.reversinglongcovid.org
November 18, 2024 at 7:36 PM
A website has launched for the baricitinib trial for Long Covid, if you’d like to participate www.reversinglongcovid.org
📣 New publication: First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib: www.clinicalmicrobiologyandinfection.org/article/S119...
#hantavirus
#hantavirus
May 30, 2026 at 5:34 PM
📣 New publication: First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib: www.clinicalmicrobiologyandinfection.org/article/S119...
#hantavirus
#hantavirus
Direct Effects of the Janus Kinase Inhibitor Baricitinib on Sensory Neurons - www.mdpi.com/1422-0067/25... highly clinically relevant work from Hans-Georg Schaible's lab. #painresearch
Direct Effects of the Janus Kinase Inhibitor Baricitinib on Sensory Neurons
Therapeutically, the Janus kinase (Jak) 1/Jak2 inhibitor baricitinib reduces the pathology of rheumatoid arthritis and may also reduce pain. Here, we investigated whether baricitinib directly affects ...
www.mdpi.com
November 27, 2024 at 4:46 PM
Direct Effects of the Janus Kinase Inhibitor Baricitinib on Sensory Neurons - www.mdpi.com/1422-0067/25... highly clinically relevant work from Hans-Georg Schaible's lab. #painresearch
FDA has approved baricitinib (Olumiant) for the treatment of pediatric patients 12 years of age and older with severe alopecia areata buff.ly/BjKSDs2
FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
buff.ly
September 27, 2026 at 9:07 PM
FDA has approved baricitinib (Olumiant) for the treatment of pediatric patients 12 years of age and older with severe alopecia areata buff.ly/BjKSDs2
2. Wes Ely announced that his National Institute of Aging-funded REVERSE-LC trial of baricitinib will now be cosponsored by NIAID as part of RECOVER-TLC and will expand from 4 to 15 sites. The sites are currently being selected, but more info on the trial is here: www.reversinglongcovid.org
REVERSE-LC
People living with Long COVID are looking for answers. REVERSE-LC is a study to see if a drug called Baricitinib can help.
www.reversinglongcovid.org
August 14, 2025 at 1:35 PM
2. Wes Ely announced that his National Institute of Aging-funded REVERSE-LC trial of baricitinib will now be cosponsored by NIAID as part of RECOVER-TLC and will expand from 4 to 15 sites. The sites are currently being selected, but more info on the trial is here: www.reversinglongcovid.org
Less cryptically: I’m on the baricitinib trial and the last two weeks have been … surprising.
October 10, 2025 at 9:50 PM
Less cryptically: I’m on the baricitinib trial and the last two weeks have been … surprising.